摘要
目的探讨前列地尔联合阿托伐他汀钙对2型糖尿病肾病合并颈动脉粥样硬化病人的粥样斑块稳定性及超敏C-反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)等炎症因子的影响。方法选择2016年1月至2018年1月在东莞巿松山湖中心医院(东莞巿第三人民医院)收治的2型糖尿病肾病合并颈动脉粥样硬化病人80例。对照组病人以阿托伐他汀钙治疗,观察组在此基础上联合前列地尔治疗。观察两组病人的粥样斑块稳定性、炎症因子及氧化应激反应水平。结果治疗2个月后两组斑块稳定性均高于治疗前(P<0.05)。观察组治疗2个月后的斑块稳定性高于对照组(P<0.05);观察组治疗2个月后的hs-CRP(2.04±0.62)μg/mL、TNF-α(22.1±2.3)ng/mL、白细胞介素6(IL-6)(4.1±0.6)pg/mL、白细胞介素8(IL-8)(6.4±0.7)pg/mL、丙二醛(MDA)(15.64±1.84)U/L、晚期氧化蛋白产物(AOPP)(41.03±5.43)μmol/L低于治疗前[hs-CRP(6.22±1.18)μg/mL、TNF-α(40.2±2.1)ng/mL、IL-6(8.2±2.1)pg/mL、IL-8(9.4±0.9)pg/mL、MDA(25.11±2.64)U/L、AOPP(75.17±6.34)μmol/L]及治疗2个月后的对照组[hs-CRP(3.25±0.93)μg/mL、TNF-α(36.4±4.2)ng/mL、IL-6(7.4±0.9)pg/mL、IL-8(7.8±1.3)pg/mL、MDA(22.11±2.67)U/L、AOPP(61.54±6.67)μmol/L],观察组治疗2个月后的谷胱甘肽过氧化物酶(GSH-Px)(234.1±33.53)μg/mL及超氧化物歧化酶(SOD)(19.34±3.32)μg/mL高于治疗前[GSH-Px(178.1±17.33)μg/mL、SOD(12.44±2.49)μg/mL]及治疗2个月后的对照组[GSH-Px(192.4±17.63)μg/mL、SOD(17.48±2.31)μg/mL],差异有统计学意义(P<0.05)。结论前列地尔联合阿托伐他汀钙可明显改善2型糖尿病肾病合并颈动脉粥样硬化病人的粥样斑块稳定性,值得临床推广。
Objective To analysis the effect Effects of alprostadil and simvastatin on atherosclerotic plaque stability and hs-CRP,TNF-α and other inflammatory factors in patients with type 2 diabetic nephropathy complicated with carotid atherosclerosis Methods 80 cases of patients type 2 diabetic nephropathy with carotid atherosclerosis were treated from January 2016 to January 2018 in Third People’s Hospital of Dongguan.The control group was treated with simvastatin,and the observation group was combined with alprostadil treatment.atherosclerotic plaque stability,inflammatory factors,and oxidative stress response in both groups were observed.Results Compared with the pre-treatment group,the plaque stability of the observation group and the control group was higher after 2 months of treatment,and the difference was statistically significant(t=6.493,5.084,6.383,5.421,4.551,5.943,P<0.05).The plaque stability after 2 months of treatment was higher,the difference was statistically significant(t=4.860,4.831,2.814,P<0.05).The patients in the observation group were treated with hs-CRP[(2.04±0.62)μg/mL vs.(3.25±0.93)μg/mL]、TNF-α[(22.1±2.3)ng/mL vs.(36.4±4.2)ng/mL、IL-6[(4.1±0.6)pg/mL vs.(7.4±0.9)pg/mL]、IL-8[(6.4±0.7)pg/mL vs.(7.8±1.3)pg/mL]、MDA[(15.64±1.84)U/L vs.(22.11±2.67)U/L,AOPP[(41.03±5.43)μmol/L vs.(61.54±6.67)μmol/L]were significantly lower,GSH-Px)[(234.1±33.53)μg/mL vs.(192.4±17.63)μg/mL],SOD[(19.34±3.32)μg/mL vs.(17.48±2.31)μg/mL]were significantly higher,the difference was statistically significant(P<0.05).Conclusion Alprostadil combined with simvastatin can significantly improve the stability of atherosclerotic plaque in patients with type 2 diabetic nephropathy with carotid atherosclerosis,reduce inflammatory factors,oxidative stress response,and improve the efficacy of patients.It is worthy of clinical promotion.
作者
叶庆邦
蔡茵瑜
卓华钦
YE Qingbang;CAI Yinyu;ZHUO Huaqin(Department of Nephrology,Third People’s Hospital of Dongguan,Chung Shan Lake Central of Dongguan,Dongguan,Guangdong 523000,China)
出处
《安徽医药》
CAS
2020年第2期398-401,共4页
Anhui Medical and Pharmaceutical Journal
基金
东莞市社会科技发展项目(201750715024134)
作者简介
通信作者:蔡茵瑜,女,主治医师,研究方向为内分泌,E⁃mail:1260013861@qq.com。
